StockData
Inhibikase Therapeutics, Inc. logo

Inhibikase Therapeutics, Inc. (IKT) stock

IKTNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 10, 2026Score 8/30
$1.38−0.07 (-4.83%)

Close on Nov 17, 2026Market cap $192.56MP/E –Yield –

Inhibikase Therapeutics price to sales ratio

The price-to-sales ratio is market cap divided by revenue over the trailing twelve months.

Inhibikase Therapeutics's price to sales ratio was 229.4× on Oct 31, 2024, against 18.6× a year earlier. Over the last 4 years it ranged from 4.1× to 229.4×, with a median of 21.0×.

Price to Sales Ratio at the end of each year

PeriodPeriod endValueChange (pts)
2024Oct 31, 2024229.4×+208.4
2023Dec 29, 202321.0×+16.9
2022Dec 30, 20224.1×−8.3
2021Dec 31, 202112.4×–

More Inhibikase Therapeutics figures

See a number that looks wrong?